The heart was thought incapable of true regeneration – we’re proving that wrong. Our NRG1B gene therapy awakens dormant regenerative pathways in cardiomyocytes, opening new frontiers in treating dilated cardiomyopathy.
Impact
This research could launch a new era of personalized regenerative medicine, replacing heart transplants with gene therapy that repairs patients’ own hearts. For children with DCM facing 2-year survival odds, this offers genuine hope for cure.
reNEW research
We are in the early stages of understanding DCM onset and discovering novel therapeutic targets. Current work focuses on characterizing cardiomyocyte response to NRG1B treatment and optimizing delivery methods.
Image description
TPM1 disease iPSC-derived cardiomyocytes after AAV6-NRG1B treatment. Cardiomyocytes (gray), nuclei (red).
Credits
Dr Marcos Sande Melon, Research Officer, Porrello and Elliott Lab, reNEW Melbourne.
